Ruxolitinib in severe COVID-19 Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

INTRODUCTION: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. METHODS: In this prospective, multicenter, single arm (compared with a hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Iastrebner, Marcelo, Castro, Joaquín, García Espina, Edgardo, Lettieri, Carolina, Payaslian, Silvio, Cuesta, María Celia, Gutiérrez, Pablo, Mandrile, Araceli, Contreras, Angela Paola, Gervasoni, Sebastián, Verde, Gabriel, Galetti, Cayetano, Minoldo, Estefanía, Caruso, Vanesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universidad Nacional de Córdoba 2021
Materias:
Artículos Originales
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760921/
https://www.ncbi.nlm.nih.gov/pubmed/34617700
http://dx.doi.org/10.3105310.31053/1853.0605.v78.n3.32800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760921/
https://www.ncbi.nlm.nih.gov/pubmed/34617700
http://dx.doi.org/10.3105310.31053/1853.0605.v78.n3.32800

Ejemplares similares